Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 59 publications
Mitigation of Oxidative Stress Pathways in the Diabetic Cornea and Lacrimal Glands Contributes to the Rapid Reversal of Diabetic Dry Eye by Naltrexone.
Journal: Investigative ophthalmology & visual science
Published: February 09, 2026
Acute Opioid Receptor Blockade Restores Vascular Endothelial Growth Factor and Astrocyte Response in db/db Mouse Brain Following Hypoxia-Ischemic Injury.
Journal: Journal of neuroscience research
Published: December 16, 2025
A Phase I Study of the Naturally Occurring Bioactive, Opioid Growth Factor, in Patients with Unresectable Hepatocellular Cancer.
Journal: Cancer investigation
Published: April 08, 2025
Reversal of Diabetic Dry Eye by Topical Opioid Receptor Blockade Follows Dual Pathways.
Journal: Investigative ophthalmology & visual science
Published: March 10, 2025
Exploring the relationships of physical, mental, and emotional symptoms and serum biomarkers of angiogenesis in multiple sclerosis.
Journal: Multiple sclerosis journal - experimental, translational and clinical
Published: November 26, 2024
Topical naltrexone increases aquaporin 5 production in the lacrimal gland and restores tear production in diabetic rats.
Journal: Experimental biology and medicine (Maywood, N.J.)
Published: March 20, 2024
Elevated Opioid Growth Factor Alters the Limbus in Type 1 Diabetic Rats.
Journal: Journal of diabetes and clinical research
Published: June 12, 2023
Safety study of topical naltrexone therapy for diabetic skin wounds is confirmed in Göttingen mini-pigs.
Journal: Drug development research
Published: March 28, 2023
Acute Low Dose Naltrexone Increases β-Endorphin and Promotes Neuronal Recovery Following Hypoxia-Ischemic Stroke in Type-2 Diabetic Mice.
Journal: Neurochemical research
Published: January 19, 2023
Sex Differences in Diabetic Ocular Surface Complications and Dysregulation of the OGF-OGFr Pathway.
Journal: Journal of diabetes and clinical research
Published: October 24, 2022
Low-dose naltrexone reduced anxiety in persons with multiple sclerosis during the COVID-19 pandemic.
Low-dose naltrexone reduced anxiety in persons with multiple sclerosis during the COVID-19 pandemic.
Journal: International immunopharmacology
Published: October 04, 2022
Last Updated: 09/26/2026